JP2024511473A5 - - Google Patents

Info

Publication number
JP2024511473A5
JP2024511473A5 JP2023558979A JP2023558979A JP2024511473A5 JP 2024511473 A5 JP2024511473 A5 JP 2024511473A5 JP 2023558979 A JP2023558979 A JP 2023558979A JP 2023558979 A JP2023558979 A JP 2023558979A JP 2024511473 A5 JP2024511473 A5 JP 2024511473A5
Authority
JP
Japan
Prior art keywords
item
formula
sirna molecule
ribonucleoside
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511473A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/021790 external-priority patent/WO2022204430A1/en
Publication of JP2024511473A publication Critical patent/JP2024511473A/ja
Publication of JP2024511473A5 publication Critical patent/JP2024511473A5/ja
Pending legal-status Critical Current

Links

JP2023558979A 2021-03-24 2022-03-24 パターン化化学修飾を有する二本鎖sirna Pending JP2024511473A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165543P 2021-03-24 2021-03-24
US63/165,543 2021-03-24
PCT/US2022/021790 WO2022204430A1 (en) 2021-03-24 2022-03-24 Double-stranded sirna having patterned chemical modifications

Publications (2)

Publication Number Publication Date
JP2024511473A JP2024511473A (ja) 2024-03-13
JP2024511473A5 true JP2024511473A5 (cg-RX-API-DMAC7.html) 2025-04-01

Family

ID=83397880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558979A Pending JP2024511473A (ja) 2021-03-24 2022-03-24 パターン化化学修飾を有する二本鎖sirna

Country Status (7)

Country Link
US (1) US20240182892A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313075A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511473A (cg-RX-API-DMAC7.html)
CN (1) CN117597133A (cg-RX-API-DMAC7.html)
AU (1) AU2022242899A1 (cg-RX-API-DMAC7.html)
CA (1) CA3214660A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022204430A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024073595A2 (en) * 2022-09-28 2024-04-04 Atalanta Therapeutics, Inc. Compositions and methods for treatment of huntington's disease
CN118202055A (zh) * 2023-02-17 2024-06-14 苏州时安生物技术有限公司 一种抑制SCN9A基因表达的siRNA、其药物组合物及用途
KR20260112707A (ko) * 2023-10-18 2026-07-20 유니버시티 오브 매사추세츠 에틸렌 글라이콜이 개질된 올리고뉴클레오타이드
TW202521696A (zh) * 2023-11-20 2025-06-01 大陸商上海舶望製藥有限公司 抑制鈉電壓門控通道α亞基9(SCN9A)表達的組合物和方法
WO2025196505A2 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181551B2 (en) * 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
BR112015013105B1 (pt) * 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
EP3929293A3 (en) * 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
BR112017021053A2 (en) * 2015-04-13 2018-08-14 Alnylam Pharmaceuticals, Inc. angiopoietin type 3 (angpt13) irna compositions and methods of use thereof
LT3329002T (lt) * 2015-07-31 2021-01-11 Alnylam Pharmaceuticals, Inc. Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
US11015198B2 (en) * 2017-04-05 2021-05-25 Silence Therapeutics Gmbh Products and compositions
WO2018237245A1 (en) * 2017-06-23 2018-12-27 University Of Massachusetts TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
SG11202003082UA (en) * 2017-11-13 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
CA3133241A1 (en) * 2019-03-15 2020-09-24 University Of Massachusetts Oligonucleotides for tissue specific apoe modulation
AU2020252020A1 (en) * 2019-03-29 2021-11-11 University Of Massachusetts Oligonucleotide-based modulation of C90RF72
US20210115442A1 (en) * 2019-08-23 2021-04-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides

Similar Documents

Publication Publication Date Title
JP6647430B2 (ja) アンチセンス核酸
JP6701139B2 (ja) アンチセンス核酸
CN110055243B (zh) 反义核酸
JP6977998B2 (ja) アンチセンス核酸
US10538763B2 (en) Compounds and methods for modulation of DUX4
JP2025165976A5 (cg-RX-API-DMAC7.html)
JP2021533804A5 (cg-RX-API-DMAC7.html)
CN107532162A (zh) 用于利用寡核苷酸编辑细胞中核酸的组合物和方法
WO2015137409A1 (ja) アンチセンス核酸
JP2021072862A (ja) B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子
JP2024521897A5 (cg-RX-API-DMAC7.html)
CN113454221A (zh) 含有三元环的双链核酸抑制剂分子
US12529053B2 (en) Double-stranded nucleic acid inhibitor molecules with shortened sense strands
JPWO2019022196A1 (ja) 一本鎖オリゴヌクレオチド
JP2021515784A5 (cg-RX-API-DMAC7.html)
CN114901823A (zh) 诱导外显子50的跳读的反义核酸
JP2024542738A5 (cg-RX-API-DMAC7.html)
JP7737667B2 (ja) 核酸複合体
CN115210376A (zh) 诱导外显子51的跳读的反义核酸
JP2024512612A5 (cg-RX-API-DMAC7.html)
CN121311592A (zh) 用于调节jak1表达的双链寡核苷酸
JP2025517341A5 (cg-RX-API-DMAC7.html)
RU2025110470A (ru) КОМПОЗИЦИИ миРНК И СПОСОБЫ ДЛЯ НАЦЕЛИВАНИЯ НА НУКЛЕИНОВЫЕ КИСЛОТЫ БЕЛКА ТАУ, АССОЦИИРОВАННОГО С МИКРОТРУБОЧКАМИ
RU2025110478A (ru) КОМПОЗИЦИИ миРНК И СПОСОБЫ ДЛЯ НАЦЕЛИВАНИЯ НА НУКЛЕИНОВЫЕ КИСЛОТЫ АЛЬФА-СИНУКЛЕИНА
WO2024228398A1 (ja) グアニン四重鎖構造を誘導するための核酸剤